MX2016012896A - Autoinmunidad y tratamiento de la esclerosis multiple. - Google Patents

Autoinmunidad y tratamiento de la esclerosis multiple.

Info

Publication number
MX2016012896A
MX2016012896A MX2016012896A MX2016012896A MX2016012896A MX 2016012896 A MX2016012896 A MX 2016012896A MX 2016012896 A MX2016012896 A MX 2016012896A MX 2016012896 A MX2016012896 A MX 2016012896A MX 2016012896 A MX2016012896 A MX 2016012896A
Authority
MX
Mexico
Prior art keywords
subject
multiple sclerosis
fasting
time period
diet
Prior art date
Application number
MX2016012896A
Other languages
English (en)
Inventor
D Longo Valter
Young Choi In
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of MX2016012896A publication Critical patent/MX2016012896A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)

Abstract

Un método para aliviar un síntoma de la esclerosis múltiple u otra enfermedad autoinmunitaria o inflamatoria incluye una etapa de identificación de un sujeto que tiene esclerosis múltiple u otra enfermedad autoinmunitaria. Se administra una dieta que imita al ayuno al sujeto durante un primer período de tiempo predeterminado, proporcionando la dieta que imita al ayuno menos de 50% de la ingesta calórica normal del sujeto. Se administra una dieta no de ayunas al sujeto durante un segundo período de tiempo después del primer período de tiempo. La dieta no de ayunas proporciona al sujeto más del 60% de ingesta calórica normal del sujeto, pero una ingesta de calorías necesaria para que el sujeto vuelva a un peso saludable norma.
MX2016012896A 2014-04-02 2015-04-02 Autoinmunidad y tratamiento de la esclerosis multiple. MX2016012896A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974189P 2014-04-02 2014-04-02
PCT/US2015/024021 WO2015153850A2 (en) 2014-04-02 2015-04-02 Autoimmunity and multiple sclerosis treatment

Publications (1)

Publication Number Publication Date
MX2016012896A true MX2016012896A (es) 2017-05-12

Family

ID=54241439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012896A MX2016012896A (es) 2014-04-02 2015-04-02 Autoinmunidad y tratamiento de la esclerosis multiple.

Country Status (10)

Country Link
US (1) US11406122B2 (es)
EP (1) EP3125904A4 (es)
JP (2) JP6727130B2 (es)
KR (1) KR20170003542A (es)
CN (1) CN107613989A (es)
AU (1) AU2015240720B2 (es)
CA (1) CA2944479C (es)
MX (1) MX2016012896A (es)
RU (1) RU2687750C2 (es)
WO (1) WO2015153850A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3125904A4 (en) 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
US11000057B2 (en) * 2015-05-06 2021-05-11 University Of Southern California Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
EP3416500B1 (en) 2016-02-15 2024-01-10 University of Southern California Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes
WO2017197076A1 (en) * 2016-05-11 2017-11-16 University Of Southern California Fasting mimicking diet (fmd) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CA3070913A1 (en) * 2017-09-12 2019-03-21 Societe Des Produits Nestle S.A. Methods for mimicking chronic caloric restriction and for imparting health benefits to an animal
WO2019178486A1 (en) 2018-03-15 2019-09-19 University Of Southern California Fasting-mimicking diet (fmd) but not water-only fasting promotes reversal of inflammation and ibd pathology
KR102216752B1 (ko) * 2019-06-03 2021-02-17 국제뇌교육종합대학원대학교 산학협력단 황칠나무 추출물을 포함하는 탈수초 질환의 예방 또는 치료용 조성물
GB201918657D0 (en) 2019-12-17 2020-01-29 Tdeltas Ltd Compounds for new use
IT202000016957A1 (it) * 2020-07-13 2022-01-13 Univ Degli Studi Di Palermo Composizione dietetica per il trattamento della depressione
US20220175007A1 (en) * 2020-12-09 2022-06-09 University Of Southern California Fasting mimicking ketogenic diet to improve immune function and vaccine response and minimize risk in adults and elderly

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121044A1 (en) * 2001-03-14 2004-06-24 John Tiano Nutritional product with high protein, low carbohydrate content and good physical stability
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
WO2008119077A1 (en) 2007-03-28 2008-10-02 University Of Southern California Induction of differential stress resistance and uses thereof
US8865646B2 (en) 2007-03-28 2014-10-21 University Of South California Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
US20110118528A1 (en) * 2009-10-22 2011-05-19 University Of Southern California Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment
ES2555032T3 (es) * 2010-01-19 2015-12-28 Mjn U.S. Holdings Llc Compensación nutricional para dieta de tipo occidental
US20130045215A1 (en) 2010-04-28 2013-02-21 University Of Southern California Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans
WO2012109353A2 (en) 2011-02-08 2012-08-16 University Of Southern California Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans
CA2844811A1 (en) * 2011-08-19 2013-02-28 European Ketogenic Weight Loss Clinics Llc Methods for weight loss and ketogenic compositions
WO2014066426A1 (en) * 2012-10-22 2014-05-01 University Of Southern California Methods and formulations promoting tissue/organ regeneration, longevity and healthspan
CN105008929B (zh) 2013-02-12 2018-10-02 南加利福尼亚大学 预防化学毒性和与年龄相关的疾病的方法和膳食
PE20151949A1 (es) * 2013-03-19 2016-01-05 Univ South Florida Composiciones y metodos para producir cetosis elevada y sostenida
AU2014284399B2 (en) 2013-07-01 2017-10-26 University Of Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP3125904A4 (en) 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment

Also Published As

Publication number Publication date
US11406122B2 (en) 2022-08-09
EP3125904A2 (en) 2017-02-08
JP2017515458A (ja) 2017-06-15
JP6727130B2 (ja) 2020-07-22
WO2015153850A2 (en) 2015-10-08
RU2016140158A (ru) 2018-05-04
KR20170003542A (ko) 2017-01-09
CN107613989A (zh) 2018-01-19
US20170027217A1 (en) 2017-02-02
JP7021794B2 (ja) 2022-02-17
RU2687750C2 (ru) 2019-05-16
AU2015240720B2 (en) 2019-12-05
CA2944479C (en) 2023-02-21
CA2944479A1 (en) 2015-10-08
JP2020096620A (ja) 2020-06-25
RU2016140158A3 (es) 2018-10-25
EP3125904A4 (en) 2017-08-30
AU2015240720A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
MX2016012896A (es) Autoinmunidad y tratamiento de la esclerosis multiple.
NZ715431A (en) Fasting condition as dietary treatment of diabetes
MX2015010320A (es) Metodos y dietas para proteger contra la quimiotoxicidad y enfermedades asociadas con la edad.
MX2016016800A (es) Metodos para el tratamiento del sobrepeso o la obesidad.
MX2018013727A (es) Dieta imitadora del ayuno (fmd) como un tratamiento inmunoregulador para enfermedades gastrointestinales autoinmunes/inflamatorias.
MX355065B (es) Método y dispositivo para conmutación de cámaras.
MX343368B (es) Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
MX2015011927A (es) Reduccion de riesgo de enfermedades autoinmune.
WO2014115033A3 (en) A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications
Nkhoma et al. Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI‐free regimens
Kwak Psychosis: case report
Zou Stevens-Johnson syndrome in a child: case report
Mangalakumar et al. Outlier genes as biomarkers of breast cancer survivability in time-series data
Chan Methylprednisolone/prednisolone
Kuznetsova et al. CONTINUING MEDICAL EDUCATION. FEATURES OF IMPLEMENTATION OF EDUCATIONAL PROGRAMS FOR GENERAL PRACTICE (FAMILY MEDICINE)
Jain et al. Anaphylaxis with intravenous immunoglobulin: a time for introspection.
Centeno Methylnaltrexone bromide
Rasmussen Acute dystonia: case report
Vebraite et al. Cognitive failure evaluation and therapy based on pharmacy practice-utilization of anti-dementia drugs and food supplements in Lithuania
Cherella Baclofen withdrawal
Sakaue Leucocytoclastic vasculitis: case report
Wilson Diarrhoea in an elderly patient: case report
Yates Bortezomib/cyclophosphamide
Esteve Olmesartan medoxomil/valsartan
Švonja et al. Nutritional status and dietary habits of young people